TerraPower Isotopes (TPI) is building its flagship current actinium-225 (ac-225) manufacturing facility in the Bellwether District of Philadelphia, Pennsylvania.
TPI's development of an East Coast manufacturing facility, along with expanding capacity in its existing Everett, Washington plant, will increase production capacity 20-fold and position the company as an important global distributor of ac-225. The project features a multi-year buildout, with production of cGMP actinium-225 beginning in 2029.
TerraPower Isotopes is part of TerraPower, a nuclear company that advances technologies across energy and healthcare. TPI is advancing the fight against cancer by bringing the next generation of isotopes to market, and its actinium-225 is currently being used in human clinical trials. This new cGMP Bellwether Laboratory will further expand ac-225's supply, certify the product with cGMP standards, and increase production levels overall to support growing global drug development needs.
"TerraPower's mission is to deliver new technologies to market that can improve lives; and the work our TerraPower Isotopes team is doing shows real promise in supporting the expansion of a diverse suite of cancer treatments using nuclear medicine," said TerraPower president and CEO Chris Levesque in a statement. "This new facility will help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments."
TPI said it evaluated more than 350 potential sites across the United States in a site selection process that included 49 site visits in eight metropolitan areas. The Bellwether District is uniquely positioned to offer the scale, proximity to critical infrastructure, and access to a life sciences and medical ecosystem that is critical to TPI and the radiopharmaceutical industry.
TerraPower is a nuclear innovation company founded by Bill Gates and a group of other investors. It serves as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement, and other opportunities.
